SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

Home・Akciju saraksts・Innate Pharma SA

I
Innate Pharma SA

Slēgts

1.108 3.17

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.058

Max

1.1219999999999999

Galvenie mērījumi
By Trading Economics
Ienākumi	-21M
Pārdošana	4.9M
EPS	-0.12
Peļņas marža	-439.177
Darbinieki	174
EBITDA	-25M

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	110M
Iepriekšējā atvēršanas cena	-2.06
Iepriekšējā slēgšanas cena	1.108

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

1.91 / 2.1 Atbalsts un pretestība

Innate Pharma SA Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 27. marts 17:33 UTC

Galvenie ziņu notikumi

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

2026. g. 27. marts 17:00 UTC

Galvenie ziņu notikumi

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

2026. g. 27. marts 16:03 UTC

Galvenie ziņu notikumi

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

2026. g. 27. marts 14:50 UTC

Galvenie tirgus virzītāji

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

2026. g. 27. marts 14:37 UTC

Iegādes, apvienošanās, pārņemšana

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

2026. g. 27. marts 14:29 UTC

Galvenie ziņu notikumi

EU Finance Ministers Tally Economic Hit of Iran War -- Update

2026. g. 27. marts 14:16 UTC

Galvenie ziņu notikumi

The Week in Oil: Mixed Signals Over U.S.-Iran Talks Keep Traders Wary

2026. g. 27. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 27. marts 19:16 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

2026. g. 27. marts 19:07 UTC

Tirgus saruna

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

2026. g. 27. marts 19:04 UTC

Tirgus saruna

Gold Rises But Can't Finish the Week Positive -- Market Talk

2026. g. 27. marts 19:03 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 27. marts 19:02 UTC

Tirgus saruna

Galvenie ziņu notikumi

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

2026. g. 27. marts 18:12 UTC

Tirgus saruna

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

2026. g. 27. marts 17:36 UTC

Galvenie ziņu notikumi

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

2026. g. 27. marts 17:34 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

2026. g. 27. marts 17:29 UTC

Tirgus saruna

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

2026. g. 27. marts 16:38 UTC

Tirgus saruna

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

2026. g. 27. marts 16:32 UTC

Tirgus saruna

Galvenie ziņu notikumi

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

2026. g. 27. marts 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 27. marts 15:43 UTC

Tirgus saruna

Galvenie ziņu notikumi

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

2026. g. 27. marts 15:25 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 27. marts 15:25 UTC

Tirgus saruna

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

2026. g. 27. marts 15:00 UTC

Galvenie ziņu notikumi

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

2026. g. 27. marts 15:00 UTC

Galvenie ziņu notikumi

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

2026. g. 27. marts 15:00 UTC

Galvenie ziņu notikumi

Fed's Barkin Says Iran War Raising Economic Uncertainty

2026. g. 27. marts 14:36 UTC

Tirgus saruna

Galvenie ziņu notikumi

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

2026. g. 27. marts 14:26 UTC

Tirgus saruna

Galvenie ziņu notikumi

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

2026. g. 27. marts 14:14 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 27. marts 14:14 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Innate Pharma SA Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Innate Pharma SA — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

1.91 / 2.1Atbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Innate Pharma SA

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.